Hodgkin lymphoma trials in Spain

In Spain 26 Also abroad 155

26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Where
Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Sevilla, Zaragoza
Age
18 years and over
People
118 worldwide
Run by
Ryvu Therapeutics S.A.
See details and how to join2024-513098-31-00 · EU 2024-513098-31-00
Phase 1/2Taking people
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Where
Badalona, Barcelona, Madrid, Málaga
Age
18 years and over
People
280 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00
Phase 1/2Taking people
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia
Age
18 years and over
People
16
Run by
Cellcentric Limited
See details and how to join2024-519498-20-00 · EU 2024-519498-20-00
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Barcelona, Madrid
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Barcelona, Cáceres, Madrid, Sevilla
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1/2Taking people
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01]
Where
Barcelona, Pamplona, Salamanca, Valencia
Age
18 years and over
People
48 worldwide
Run by
Cellectis
See details and how to joinNCT05607420 · EU 2022-501607-27-00
Phase 1Taking people
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, Valencia
Age
18 years and over
People
52 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-505185-28-00 · EU 2023-505185-28-00
Phase 1Not yet taking people in Spain
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona
Age
18 years and over
People
34 worldwide
Run by
Kyowa Kirin Inc.
See details and how to joinNCT07192471 · EU 2025-522523-96-00
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Barcelona, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
L'Hospitalet de Llobregat, Madrid
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1Taking people
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Where
Barcelona, Madrid
Age
0 years to 18 years
People
30 worldwide
Run by
Autolus Limited
See details and how to joinNCT06173518 · EU 2023-506307-26-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 1/2Taking people
A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
Where
Barcelona, Madrid, Salamanca, Valencia
Age
18 years and over
People
30 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2025-524915-36-00 · EU 2025-524915-36-00
Phase 1Taking people
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Where
L'Hospitalet de Llobregat, Madrid, Salamanca, Valencia
Age
18 years and over
People
121 worldwide
Run by
ADC Therapeutics SA
See details and how to joinNCT04970901 · EU 2024-512089-32-00
Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Barcelona
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 1Taking people
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
Where
Barcelona, Madrid
Age
18 years and over
People
42 worldwide
Run by
Regeneron Pharmaceuticals Inc.
See details and how to joinNCT05685173 · EU 2022-502137-26-00
Phase 3Taking people
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Where
Barcelona, L'Hospitalet de Llobregat, Pamplona
Age
16 years to 69 years
People
1,042 worldwide
Run by
University College, London
See details and how to joinNCT04685616 · EU 2022-500031-37-00
Phase 3Taking people
A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
Where
Granada, Madrid, Pamplona
Age
18 years and over
People
132 worldwide
Run by
Regeneron Pharmaceuticals Inc.
See details and how to joinNCT06230224 · EU 2022-502783-21-00
Phase 1/2Taking people
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Where
Badalona, Barcelona, El Palmar, Murcia, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
23 worldwide
Run by
BioInvent International AB
See details and how to joinNCT03571568 · EU 2024-512972-36-00
Phase 2/3Taking people
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Where
Esplugues de Llobregat, Madrid, Valencia
Age
Up to 25 years
People
210 worldwide
Run by
University of Birmingham
See details and how to joinNCT05991388 · EU 2024-510575-38-00
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 1/2Taking people
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
Where
Barcelona, Sevilla
Age
18 years and over
People
40
Run by
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
See details and how to join2024-519790-19-00 · EU 2024-519790-19-00
Phase 2Taking people
Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles- RAFTING
Where
Badalona, Barcelona, Burgos, León, L'Hospitalet de Llobregat, Madrid, Oviedo, Palma, Salamanca, Santander, Sevilla
Age
18 years and over
People
145 worldwide
Run by
Medical University Of Gdansk
See details and how to join2024-515063-66-00 · EU 2024-515063-66-00